UCB's BIMZELX Outperforms AbbVie's SKYRIZI in Psoriatic Arthritis Trial
Event summary
- UCB's BIMZELX demonstrated superior ACR50 joint outcomes compared to AbbVie's SKYRIZI in the BE BOLD trial at Week 16 (49.1% vs. 38.4%, p=0.0078).
- BIMZELX also showed numerically higher responses in secondary endpoints, including complete skin clearance (PASI100) at Week 16 (53.4% vs. 46.6%).
- No new safety signals were identified in either treatment arm, with similar rates of adverse events.
- Results will be presented at the 2026 EULAR Annual Meeting in London on June 6.
The big picture
UCB's BIMZELX is the first approved biologic therapy to demonstrate statistically significant superiority in ACR50 joint outcomes in a head-to-head trial for psoriatic arthritis. This positions BIMZELX as a potential market leader in the treatment of psoriatic arthritis, challenging AbbVie's SKYRIZI. The results underscore the importance of head-to-head trials in comparative clinical research, providing high-quality evidence to support treatment decisions in chronic inflammatory diseases.
What we're watching
- Market Positioning
- Whether UCB can leverage these results to gain market share against AbbVie's SKYRIZI in the psoriatic arthritis space.
- Regulatory Approvals
- The pace at which UCB can secure additional regulatory approvals for BIMZELX based on these trial outcomes.
- Long-term Efficacy
- How sustained the efficacy and safety of BIMZELX will be in longer-term follow-up data from the BE BOLD trial.
Related topics